2024-10-10T17:23:14+08:002022-07-08|
Contact Information
Title
Head of Centre for Innovation and Entrepreneurship, Professor
Office
(Office) E12-3021 / (Lab) N22-3009a
Phone
(Office) +853 8822 9940 / (Lab) +853 8822 2524
Email
lhleung@um.edu.mo
Consultation Hours

Tue 15:00 – 17:00

Teaching

HSCI4007 Translational Medicine

Research Team
Name Position Office Phone Email
Dr Jumin HUANGResearch Assistant ProfessorN22-3003+853 8822 2964juminhuang@um.edu.mo
Tingting ZHAOPost-doctoral FellowN22-3004+853 8822 2964tingtingzhao@um.edu.mo
Yinrui GUOPost-doctoral Fellow (Macau Young Scholar Program)N22-3004+853 8822 2964yinruiguo@um.edu.mo
Jin LIAOResearch AssistantN22-3003+853 8822 2964jinliao@um.edu.mo
Rongsheng SHENResearch AssistantN22-3004+853 8822 2964rongshengshen@um.edu.mo
Yongkai LiangResearch AssistantN22-3003+853 8822 2964yongkailiang@um.edu.mo
Jiahui XUPhD StudentN22-3003+853 8822 2964yc27654@um.edu.mo
Ziming WANGPhD StudentN22-3003+853 8822 2964yc27657@um.edu.mo
Ziwen YUPhD StudentN22-3003+853 8822 2964yc37632@um.edu.mo
Xiaoxian KUANGPhD StudentN22-3003+853 8822 2964yc37189@um.edu.mo
Shuyun JIANGPhD StudentN22-3003+853 8822 2964yc37643@um.edu.mo
Chun XIEPhD StudentN22-3003+853 8822 2964yc47691@um.edu.mo
Shujie SONGPhD StudentN22-3003+853 8822 2964yc47620@um.edu.mo
Yuqing NUPhD StudentN22-3003+853 8822 2964yc47602@um.edu.mo
Education
PhD Department of Physiology, The Chinese University of Hong Kong, 2006
MPhil Department of Biochemistry, The Chinese University of Hong Kong, 2003
BSc Department of Biology and Department of Biochemistry, The Chinese University of Hong Kong, 2001

 

Position
08/2023 – Present Head, Centre for Innovation and Entrepreneurship, University of Macau
07/2022 – Present Professor, Faculty of Health Sciences, University of Macau
05/2022 – Present Distinguished Professor, The Third People’s Hospital of Chengdu, Chengdu, China
11/2020 – 05/2022 Executive Director, Dr. Neher’s Biophysics Laboratory for Innovative Drug Discovery, Macau University of Science and Technology
09/2018 – Present Adjunct Professor, Zhuhai Hospital of Integrated Traditional Chinese & Western Medicine
11/2017 – Present Project consultant, Janssen Pharmaceuticals Inc (Pharmaceutical companies of Johnson & Johnson)
10/2017 – 12/2019 Adjunct Professor, The first Affiliated Hospital of Guangzhou Medical University
09/2015 – Present Visiting Professor, Department of Internal Medicine, Taihei Hospital, Hubei, China
07/2015 – 05/2022 Associate Professor, State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology
07/2013 – 05/2022 Assistant Director, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology
09/2011 – 06/2015 Assistant Professor, State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology
03/2011 – 08/2011 Post-doctoral Research Fellow, School of Chinese Medicine, Hong Kong Baptist University
07/2006 – 02/2011 Post-doctoral Research Fellow, Department of Pathology, Queen Mary Hospital, The University of Hong Kong
Research Interests
Precision Oncology: Investigation of novel biomarker to predict cancer drug response and precision treatment based on -omics technologies.

Anti-cancer drug discovery: Discovery of novel small molecules and Chinese herbal medicines for effective treatment of drug resistant cancer cells.

Cancer Biology: Investigation the role of cancer metabolism and redox balance in cancer.
Representative Publications
  1. Huang JM, Wang XR, Wang ZM, Deng LY, Wang YW, Tang YP#, Luo LX# & Leung EL#. Extracellular vesicles as a novel mediator of interkingdom communication. Cytokine and Growth Factor Reviews. 2023 (accepted)
  2. Leung EL#*, Li RZ#, Fan XX#, Wang LY, Wang Y, Jiang ZB, Huang JM, Pan HD, Fan Y, Xu HM, Wang F, Rui HP, Wong P, Sumatoh H, Fehlings M, Nardin A, Gavine P, Zhou LE, Cao YB* and Liu L*. Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy. Nature Communication. 2023 (accepted)
  3. Huang JM, Duan FG, Xie C, Xu JH, Zhang YZ, Wang YW, Tang YP* & Leung EL*. Microbes mediated immunogenic cell death in cancer immunotherapy. Immunological Reviews. 2023 (accepted)
  4. Wang J, Li RZ, Wang WJ, Pan HD, Xie C, Yau LF, Wang XX, Long WL, Chen RH, Liang TL, Ma LR, Li JX, Huang JM, Wu QB, Liu L#, He JX# and Leung EL#. CERS4 predicts positive anti-PD-1 response and promotes immunomodulation through Rhob-mediated suppression of CD8+Tim3+ exhausted T cells in non-small cell lung cancer. Pharmacological Research. 2023 (accepted)
  5. Zhang JH, He JX, Huang JM, Li XF, Fan XQ, Li WB, Wu GF, Xie C, Fan XX, Zhang JM#, Yao XJ#, Wang R# and Leung EL#. Pharmacokinetics, absorption and transport mechanism for ginseng polysaccharides. Biomedicine & Pharmacotherapy. 2023 (accepted)
  6. Zhang J, Liu P, Chen J, Yao D, Liu Q, Zhang J, Zhang HW, Leung EL*, Yao XJ* and Liu L*. Upgrade of Chrysomycin A as a novel Topoisomerase II inhibitor to Curb KRAS-mutant lung adenocarcinoma progression. Pharmacological Research 2023 Jan; 187:106565.doi: 10.101016/j.phrs.2022.106565. Epub 2022 Nov 19
  7. Leung EL, Fan XX, Huang JM, Huang C, Lin H & Cao YB. Holistic immunomodation for small cell lung cancer. Seminar in Cancer Biology 2023 Jan;88:96-105. doi: 10.1016/j.semcancer.2022.11.012. Epub 2022 Dec 5.
  8. Xie Y, Feng SL, He F, Yan PY, Yao XJ, Fan XX, Leung EL* and Zhou H*. Down regulating Nrf2 by tangeretin reverses multiple drug resistance to both chemotherapy and EGFR tyrosine kinase inhibitors in lung cancer. Pharmacological Research 2022 (accepted).
  9. Fan XQ, Mai CT, Zuo L, Huang JM, Xie C, Jiang ZB, Li RZ, Yao XJ, Fan XX, Wu QB, Yan PY, Liu L, Chen JX*, Xie Y* and Leung EL*. Herbal formula BWBDS alleviates polymicrobial sepsis-induced liver injury via increasing the gut microbiota Lactobacillus johnsonii and regulating macrophage anti-inflammatory activity in mice. Acta Pharmaceutica Sinica B 2023 Mar;13(3):1164-1179.
  10. Leung EL*#, Huang JM#, Zhang JM#, Zhang JH, Wang MF, Zhu YZ, Meng ZQ, Yu HJ, Neher E, Ma LJ *, Yao XJ*. Novel anticancer strategy by targeting the gut microbial neurotransmitter signaling to overcome immunotherapy resistance. Antioxidants and Redox Signaling. 2022 Aug 26 doi: 10.1089/ars.2021.0243. Online ahead of print
  11. Wang XR, Jiang ZB, Xu C, Meng WY, Liu P, Zhang YZ, Xie C, Yu JY, Xie YJ, Liang TL, Yan HX, Fan XX, Yao XJ*, Wu QB* and Leung EL*. Andrographolide suppresses non-small-cell lung cancer progression through induction of autophagy and antitumor immune response. Pharmacological Research. 2022; 179:106198. https://doi.org/10.1016/j.phrs.2022.106198
  12. Zhang JM#, Zhang JH#, Liu Q, Fan XX, Leung EL*, Yao XJ*, Liu L*. Resistance looms for KRAS G12C inhibitors and rational tackling strategies. Pharmacology & Therapeutics. 2022; 229:108050. https://doi.org/10.1016/j.pharmthera.2021.108050
  13. Li JX, Li RZ, Sun A, Zhou H, Neher E, Yang JS, Huang JM, Zhang YZ, Jiang ZB, Liang TL, Ma LR, Wang J, Wang XR, Fan XQ, Huang J, Xie Y, Liu L, Tang L, Leung EL, Yan PY. Metabolomics and integrated network pharmacology analysis reveal Tricin as the active anti-cancer component of Weijing decoction by suppression of PRKCA and sphingolipid signaling. Pharmacological Research. 2021; 171:105574. https://doi.org/10.1016/j.phrs.2021.105574
  14. Jiang ZB, Wang WJ, Xu C, Xie YJ, Wang XR, Zhang YZ, Huang JM, Huang M, Xie C, Liu P, Fan XX, Ma YP, Yan PY, Liu L, Yao XJ, Wu QB, Leung EL. Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer. Cancer Letters. 2021; 515:36-48. https://doi.org/10.1016/j.canlet.2021.05.019
  15. Huang J#, Liu D#, Wang Y#, Liu L, Li J, Yuan J, Jiang Z, Jiang Z, Hsiao WW, Liu H, Khan I, Xie Y, Wu J, Xie Y, Zhang Y, Fu Y, Liao J, Wang W, Lai H, Shi A, Cai J, Luo L, Li R, Yao X, Fan X, Wu Q, Liu Z, Yan P, Lu J, Yang M, Wang L, Cao Y*, Wei H*, Leung EL*. Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the anti-tumor effect of anti-programmed cell death 1 /programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy. Gut. 2021; 71(4):734-745. https://doi.org/10.1136/gutjnl-2020-321031
  16. Jiang ZB, Xu C, Wang W, Zhang YZ, Huang JM, Xie YJ, Wang QQ, Fan XX, Yao XJ, Xie C, Wang XR, Yan PY, Ma YP, Wu QB, Leung EL. Plumbagin suppresses non-small cell lung cancer progression through downregulating ARF1 and by elevating CD8+ cells. Pharmacological Research. 2021; 169:105656. https://doi.org/10.1016/j.phrs.2021.105656
  17. Jiang ZB, Huang JM, Xie YJ, Zhang YZ, Chan C, Lai HL, Wang WJ, Yao XJ, Fan XX, Wu QB, Xie C, Wang MF*, Leung EL*. Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis. Journal of Experimental & Clinical Cancer Research. 2020; 39:249.0020https://doi.org/10.1186/s13046-020-01741-5
  18. Lai HL#, Fan XX#, Liu RZ#, Wang YW, Zhang JM, Liu L, Neher E*, Yao XJ* and Leung EL*. Roles of ion fluxes, metabolism, and redox balance in cancer therapy. Antioxidants & Redox Signaling. 2020 Oct 29(ja). https://doi.org/10.1089/ars.2020.8125
  19. Leung EL#, Lai HL#, Li RZ, Pan HD, Jiang ZB Li Y, Duan FG, Xu JH, Zhang YZ, Shi AX, Wei CL, Zhang FY, Yao XJ and Liang Liu. Roles of serum amyloid A1 protein isoforms in rheumatoid arthritis. Engineering. 2022; 10:174-182. https://doi.org/10.1016/j.eng.2020.08.018
  20. Leung EL*, Xu S*. Traditional Chinese Medicine in Cardiovascular Drug Discovery. Pharmacological Research. 2020 Oct 1;160:105168. https://doi.org/10.1016/j.phrs.2020.105168
  21. Wang WJ, Mao LF, Lai HL, Wang YW, Jiang ZB, Li W, Huang JM, Xie YJ, Xu C, Liu P, Li YM, Leung EL*, Yao XJ*. Dolutegravir derivative inhibits proliferation and induces apoptosis of non-small cell lung cancer cells via calcium signaling pathway. Pharmacological Research. 2020 Nov 1;161:105129. https://doi.org/10.1016/j.phrs.2020.105129
  22. Luo S, Xu J, Jiang Z, Liu L, Wu Q, Leung EL*, Leung AP*. Artificial Intelligence-Based Collaborative Filtering Method with Ensemble Learning for Personalized Lung Cancer Medicine without Genetic Sequencing. Pharmacological Research. 2020 Oct 1;160:105037. https://doi.org/10.1016/j.phrs.2020.105037
  23. Xie YJ, Gao WN, Wu QB, Yao XJ, Jiang ZB, Wang YW, Wang WJ, Li W, Hussain S, Liu L, Leung EL*, Fan XX*. Chelidonine Selectively Inhibits the Growth of Gefitinib-resistant Non-small Cell Lung Cancer Cells through the EGFR-AMPK Pathway. Pharmacological Research. 2020 May 25:104934. https://doi.org/10.1016/j.phrs.2020.104934
  24. Leung EL* & Wu QB*. Association of Dietary Fiber and Yogurt Consumption With Lung Cancer Risk. JAMA Oncology. 2020 May 1;6(5):788-. https://doi.org/10.1001/jamaoncol.2020.0261
  25. Leung EL* & Wu QB*. Commentary on Ge et al. “Insomania and risk of mortality form all-cause, cardiovascular disease, and cancer: Systematic review and meta-analysis of prospective cohort studies. Sleep Medicine Reviews. 2020 Jan 8;50:101257. https://doi.org/10.1016/j.smrv.2019.101257
  26. Wei CL, Zhang DZ, Cheng JL, Chen X, Fan XX, Xie C, Yao XJ, Wang YW, Jiang ZB, Fu JZ* and Leung EL*. Cordycepin Inhibits Drug-resistance Non-small Cell Lung Cancer Progression by Activating AMPK Signaling Pathway. Pharmacological Research. 2019 Jun 1;144:79-89. https://doi.org/10.1016/j.phrs.2019.03.011
  27. Fan XX#, Pan HD#, Li Y, Guo RJ, Leung EL*, Liu L*. Novel therapeutic strategy for cancer and autoimmune conditions: Modulating cell metabolism and redox capacity. Pharmacology & Therapeutics. 2018 Nov 1;191:148-61. https://doi.org/10.1016/j.pharmthera.2018.06.010
  28. Leung EL#, Luo LX#, Liu ZQ, Wong VKW, Lu LL, Xie Y, Zhang N, Qu YQ, Fan XX, Li Y, Huang M, Xiao DK, Huang J, Zhou YL, He JX, Ding J, Yao XJ*, Ward DC*, Liu L*. Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity. Cell Death & Disease. 2018 Feb 13;9(2):1-5. https://doi.org/10.1038/s41419-017-0065-9
  29. Fan XX#, Leung EL#, Xie Y, Liu ZQ, Zheng YF, Yao XJ, Lu LL, Wu JL, He JX, Yuan ZW, Fu JJ, Wei CL, Huang J, Xiao DK, Luo LX, Jiang ZB, Zhou YL, Kam RK, Liu L. Suppression of Lipogenesis via Reactive Oxygen Species-AMPK Signaling for Treating Malignant and Proliferative Diseases. Antioxidants & Redox Signaling (Cover Story). 2018 Feb 10;28(5):339-57. https://doi.org/10.1089/ars.2017.7090
  30. Leung EL#, Fan XX#, Wong MP, Jiang ZH, Liu ZQ, Yao XJ, Lu LL, Zhou YL, Yau LF, Tin PC, Liu L. Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation. Antioxidants & Redox Signaling (Cover Story). 2016 Feb 10;24(5):263-79. https://doi.org/10.1089/ars.2015.6420
Full Publications List
Research Grants
09/2021 – 08/2024 Jointly Funded Scientific Research Project by the Ministry of Science and Technology of the People’s Republic of China and the Macao Science and Technology Development Fund (2021/2022) (0056/2020/AMJ)
Title: Design, synthesis and anti-cancer activity study of novel inhibitors targeting drug resistant ALK mutants
MUST: PI: Leung EL, Co-I: Yao XJ, Fan XX, Liu L, Cao YB, Li RZ. MOP 1,850,000 (Equivalent to USD 23,718) (ongoing)
05/2021 – 04/2024 Macao Science and Technology Development Fund 2021/2024 (0111/2020/A3)
Title: Investigation of the combinational treatment effect of new form of ginseng polysaccharides with anti-PD1/PDL1 immunotherapy for treatment of lung cancer
PI: Leung EL, Co-I: Liu L, Cao YB, Fan XX, Wei H, Liu D
MOP 1,800,000 (Equivalent to USD 230,769.23) (Ongoing)
2020 – 2023 Macao Science and Technology Development Fund
Funding Scheme for Laboratories and R&D Center (001/2020/ALC)
Title: Dr. Neher’s Biophysics Laboratory for Innovative drug research
PI: Ewin Neher (1991 Nobel Laureate in Physiology and Medicine), Co-PI: Leung EL
MOP 17,000,000 (Equivalent to USD 2,179,487) (Ongoing)
2018 – 2019 Jointly Funded Scientific Research Project by NSFC and the Macao Science and Technology Development Fund (032/2018/AFJ)
Title: Studies on the effectiveness of Ermiao San classified formula for rheumatoid arthritis therapy based on Chinmedomics
Macao MUST; PI: Liu L, Co-I: Zhou H, Leung EL, Li T, Wong VKW and Xie Y
MOP 2,015,000 (Ongoing)
01/2019 – 12/2022 NSFC The General Program
Title: The role and molecular mechanism of DNA methyltransferase inhibiting colon cancer and its effect on the efficacy of traditional Chinese medicine kaempferol
PI: Lin Lin Lu, Co-I: Leung EL, Wu Peng
RMB 590,000 (Equivalent to USD 75,641) (Ongoing)
11/2018 – 12/2021 Macao Science and Technology Development Fund 2018/2021
Title: Modulation of gut microbiota to enhance efficacy of anti-PD1 immunotherapy in non-small cell lung cancer
PI: Leung EL, Co-I: Liu L, Cao YB, Hsiao WL, Fan XX
MOP 2,976,800 (Equivalent to USD 381,641) (Ongoing)
— 2018 National Natural Science Foundation of China Overseas, Hong Kong and Macao Scholars Cooperative Research Fund (Overseas outstanding youth)
Title: Targeting T cell metabolic checkpoint to restore anti-cancer activity using Chinese herbal medicine
PI: Leung EL & Zhongqiu Liu
RMB 180,000 (Completed)
— Industrial grant (Supported by Macau Biotech. Co. Ltd)
“The application of single cell biochip to predict drug resistance in lung cancer” HKD500,000 (Ongoing)
(Equivalent to USD 64,103)
Macan Biotech Co. Ltd
PI: Leung EL
HKD500,000 (Completed)
— Industrial grant (Supported by Janssen Pharmaceuticals Inc., Pharmaceutical companies of Johnson & Johnson)
“Immunophenotying, molecular analysis and functional characterization of CD38 expressing cells and/or other immune populations in response to pembrolizumab in Chinese NSCLC patients”
PI: Leung EL
HKD 4,600,000 (Equivalent to USD 589, 744) (Ongoing)
05/2016 – 04/2019 Macao Science and Technology Development Fund 2015/2016
Title: Preclinical studies of a novel therapy for aggressive T-cell malignancies
PI: Ma YP, Co-I: Leung EL, Lan FS, Zieve G, Huang SM
MOP 3,070,000 (Equivalent to USD 383,750) (Completed)
05/2016 – 04/2019 Macao Science and Technology Development Fund 2015/2016
Title: Role and therapeutic intervention of reactive oxygen species and redox balance in regulation of non-small cell lung cancer
PI: Leung EL, Co-I: Ding J, He JH, Huang M, Tan MJ, Liu H & Liu ZQ
MOP 3,657,200(Equivalent to USD 457,150) (Completed)
06/2015 – 06/2016 Macao Science and Technology Development Fund 2015/2016
Title: Next SeqTM 500 Next generation DNA sequencer
PI: Leung EL
MOP3,833,270 (Equivalent to USD 491,445) (Completed)
06/2015 – 06/2016 Macao Science and Technology Development Fund 2015/2016
Title: Next SeqTM 500 Next generation DNA sequencer work station
PI: Leung EL
MOP2,250,000 (Equivalent to USD 288,462) (Completed)
2014 – 2015 Jointly Funded Scientific Research Project by the Ministry of Science and Technology of the People’s Republic of China and the Macao Science and Technology Development Fund
Title: Identification of novel metabolic biomarkers associated with lung adenocarcinoma target-based therapy resistance for network-based drug discovery with Chinese herbal medicine
Macao MUST; PI: Leung EL, Co-I: Wong VKW, Yao XJ, Ma WZ, He JX
Shanghai Institute of Materia Medica, Chinese Academy of Sciences; Advisor: Academician Ding Jian, PI: Huang M, Tan MJ, Xie ZQ, Ai J and Huang X
MOP 2,628,000 & RMB 1,760,000 (Equivalent to USD 603,500) (Completed)
12/2013 – 11/2015 Macao Science and Technology Development Fund 2012/2013
Title: Investigation on the novel candidate anti-cancer drug from Chinese herbal medicine by modulating metabolic profiles of cancer cells
PI: Leung EL, Co-I: Wong MP, He JH & Chow LW
MOP 2,481,000 (Equivalent to USD 318,000) (Completed)
09/2013 – 08/2014 Macao Foundation 2012/2013
Title: Investigation on the novel candidate anti-cancer drug from Chinese herbal medicine by modulating metabolic profiles of cancer cells
PI: Leung EL
MOP 100, 000 (Equivalent to USD 12, 820) (Completed)
06/2012 – 05/2014 Macao Science and Technology Development Fund 2011/2012
Title: Identification of candidate agents and novel molecular targets for treating Gefitinib-resistant non-small cell lung cancer (NSCLC)
PI: Leung EL, Co-I: Cao ZW & Wong MP
MOP 2,016,000 (Equivalent to USD 258,000) (Completed)
09/2011 – 08/2012 Macao Foundation 2011/2012
Title: Investigating candidate agents derived from Chinese medicinal herbs for treating Gefitinib-resistant non-small cell lung cancer (NSCLC)
PI: Leung EL
MOP 50, 000 (Equivalent to USD 6250) (Completed)
Patents
US Patent

  1. Methods for Novel Drug Discovery, Treatment and Selective Targeting for Gefitinib-Resistant Non-Small-Cell Lung Cancer Harboring T790M Mutation. Leung EL, Liu L and Fan XX (US Patent No. US 9439898 B2)
  2. Method for Treating Gefitinib-Resistant Non-Small-Cell Lung Cancer. Leung EL, Fan XX, Liu L and Jiang ZB (US Patent No. US 9597299 B2)
  3. Oncogene ROS1 Kinase Inhibitor. Yao XJ, Leung EL, Luo LX, Zhou YL and Liu L. (US Patent No. US 9526722 B1)
  4. Identification of New AMPK Activator for Treatment of Lung Cancer. Leung EL, Yao XJ, Wong VKW, Liu L and Chen X (US Patent No. US 9364469 B1)
  5. Identification of New Chemical Structure as AMPK Activator for Treatment at EGFRL858R/T790M Double Mutation Non-Small Cell Lung Cancer. (Method to treat lung cancer) Liu L, Leung EL, Yao XJ, Wong VKW and Chen X (US Patent No. US 9855250 B1)
  6. Method of Treating Cancer (Mitoxantrone). Yao XJ, Leung EL, Luo LX, Hsiao WL and Liu L (US Patent No. US 9522125 B1)
  7. Novel ROS1 Inhibitor and Its Use (C498-0065). Yao XJ, Leung EL, Luo LX and Liu L (US Patent No. US 9962378 B2)
  8. Oncogenic ROS1 and ALK Kinase Inhibitor (G341-0312). Yao XJ, Leung EL, Luo LX and Liu L (US Patent No. US 9782400 B2)
  9. ALK Kinase Inhibitor and Its Use. Yao XJ, Leung EL, Luo LX and Liang L (US Patent No. US 10111876 B2)
  10. Hydroxynaphthoquinone Compounds (Shikonin) for Treating of Non-Small Cell Lung Cancer. Liu L, Leung EL, Li X, Fan XX (US Patent No. US 9913811 B2)
  11. A Method for Treating Lung Cancer (PKM2 activator). Liu L, Leung EL, Yao XJ and Li RZ (US Patent No. US 9744145 B1)
  12. Method of Identifying a Gene Associated with a Disease or Pathological Condition of the Disease. Liu L, Leung EL, Yao XJ, Li Y and Pan HD. (US Patent No. US 10787708 B2)
  13. Methods of Treating Cancer (BPTF small molecule). Leung EL, Xiao XJ, Liu L, Xu JH, Li Y and Wang QQ (US Patent No. US 10208028 B1)
  14. Identification of a Novel and Potential PRMT5 Inhibitor with Indole Scaffold in Non-Small Cell Lung Cancer. Yao XJ, Leung EL, Liu L, Wang QQ, Xu JH and Li Y. (US Patent No. US 10702500 B2)
  15. Method of Treating Cancer (KRAS SOS inhibitor 1). Yao XJ, Leung EL, Liu L, Fan XX, Xie C. (US Patent No. US 9884046 B1).
  16. Method of Treating Lung Cancer (KRAS SOS inhibitor 2). Yao XJ, Leung EL, Liu L, Fan XX, Xie C. (US Patent No. US 9884047 B1)
  17. Combinational Treatment of Ras-Positive Diseases with PDE Delta Inhibitor and Direct Autophagy Inhibitor. Liang Liu, Ward DC, Leung EL, Yao XJ, Wong VKW, Luo LX. (US Patent No. US 9861623 B1)

Australia Patent

  1. Identification of New AMPK Activator for Treatment of Lung Cancer. Leung EL, Yao XJ, Wong VKW, Liu L and Chen X (Australia Patent No. 2015101612)
  2. Identification of New Chemical Structure as AMPK Activator for Treatment at EGFRL858R/T790M Double Mutation Non-Small Cell Lung Cancer. (Method to treat lung cancer) Liu L, Leung EL, Yao XJ, Wong VKW and Chen X (Australia Patent No. 2016102096)
  3. Method of Treating Cancer (Mitoxantrone). Yao XJ, Leung EL, Luo LX, Hsiao WL and Liu L (Australia Patent No. 2015101712)
  4. Novel ROS1 Inhibitor and Its Use (C498-0065). Yao XJ, Leung EL, Luo LX and Liu L (Australia Patent No. 2015101598)
  5. Oncogenic ROS1 and ALK Kinase Inhibitor (G341-0312). Yao XJ, Leung EL, Luo LX and Liu L (Australia Patent No. 2015101722)
  6. PDE delta Inhibitor for the Treatment of Cancer. Yao XJ, Leung EL, Luo LX and Liu L; Australia Patent No. 2015101666)
  7. ALK Kinase Inhibitor and Its Use. Yao XJ, Leung EL, Luo LX and Liang L (Australia Patent No. 2016101467)
  8. Hydroxynaphthoquinone Compounds (Shikonin) for Treating of Non-Small Cell Lung Cancer. Liu L, Leung EL, Li X, Fan XX (Australia Patent No. 2016100891)
  9. A Method for Treating Lung Cancer (PKM2 activator). Liu L, Leung EL, Yao XJ and Li RZ (Australia Patent No. 2017100105)
  10. Method of Identifying a Gene Associated with a Disease or Pathological Condition of the Disease. Liu L, Leung EL, Yao XJ, Li Y and Pan HD. (Australia Patent No. 2017100960)
  11. Bufadienolide for Treatment of Non-Small Cell Lung Cancer. Liu L, Leung EL, Yao XJ, Li RZ and Fan XX. (Australia Patent No. 2017100644)
  12. Methods of Treating Cancer (BPTF small molecule). Leung EL, Xiao XJ, Liu L, Xu JH, Li Y and Wang QQ (Australia Patent No. 2018100077)
  13. Identification of a Novel and Potential PRMT5 Inhibitor with Indole Scaffold in Non-Small Cell Lung Cancer. Yao XJ, Leung EL, Liu L, Wang QQ, Xu JH and Li Y. (Australia Patent No. 2018100078)
  14. Method of Treating Cancer (KRAS SOS inhibitor 1). Yao XJ, Leung EL, Liu L, Fan XX, Xie C. (Australia Patent No. 2017101048).
  15. Method of Treating Cancer (KRAS SOS inhibitor 2). Yao XJ, Leung EL, Liu L, Fan XX, Xie C. (Australia Patent No. 2017101044)
  16. Combinational Treatment of Ras-Positive Diseases with PDE Delta Inhibitor and Direct Autophagy Inhibitor. Liang Liu, Ward DC, Leung EL, Yao XJ, Wong VKW, Luo LX. (Australia Patent No. 2016102067)
  17. Identification of a Novel PDE Delta Inhibitor Impairs Oncogenic KRAS Signaling. Yao XJ, Leung EL, Luo LX and Liu L. (Australia Patent No. 2018101501)
  18. Method and Kit for Treating Cancer Through Combination Therapy. Leung EL, Jiang ZH, Hsiao WL, Liu L and Luo LX. (Australia Patent No. 2018101488).
  19. Methods for Treating Cancer (3039-0164 PRMT5 inhibitor). Yao XJ, Leung EL, Liu L，Xu JH，Wang QQ and Li Y. (Australia Patent No. 2018100188)
  20. Method of Selectively Inhibiting Mpges-1. Chen CS, Leung EL, Liu JX, Liu L, Luo JF, Zhou H. (Australia Patent No. 2017101212)
  21. Medicinal Composition Comprising a Non-Coding RNA Molecule and an Antibody Targeting a Tumor Antigen. Jiang ZH, Yau LF, Tong TT, Huang H, Hu K and Leung EL (Australia Patent No. 2020103404

China patent

  1. 用於通過聯合療法來治療癌症的方法及試劑盒。梁麗嫻，姜志宏，劉良，蕭文鸞，黃居敏 (China patent No. CN111000859A, filed)
  2. 組合物、其在製備腫瘤免疫治療藥物中的應用及藥物組合物。梁麗嫻，姜志宏，蕭文鸞，劉良，黃居敏 (China patent No. CN110170053A, filed)
  3. 一種 NHTD 的合成方法。謝瑩，姚和權，梁麗嫻，姚小軍，劉良，李宣儀 (China patent No. CN111362894A, filed)
  4. 一種中藥組合物、提取物及其製備方法與應用。梁麗嫻，姚小軍，劉良，賴煥玲，王文君 (China patent No. CN112386654A, filed)
  5. 一種 PD-1 抑制劑及其製備方法與應用。顏培宇，梁麗嫻，李佳馨，李潤澤，劉良 (China patent No. CN112915170A, filed)
  6. 包含非編碼 RNA 分子和靶向腫瘤抗原的抗體的藥物組合物。姜志宏，丘利芳，佟天天，黃浩，胡姱，梁麗嫻 (China patent No. CN 112089835 B, granted)
  7. 一種中藥組合物、提取物及其製備方法與應用。 梁麗嫻 姚小軍 劉良 賴煥玲 王文君 (China patent No. CN 112386654 B, granted)
Awards
2020 National TCM Inheritance and Innovation Talent Project, 2020 Young Qi Huang Scholar Award (Talent Project) 2020
Only 100 awardees in whole China in total
2018 Science and Technology Award of Higher Education of China (First Class), Ministry of Education, China 2018
Title: New mechanism of abnormal cell proliferation and cell differentiation
2018 Zhong Zhu Medicine & Life Science Excellent Teacher Award (Research Award-Special Class) 2018
2017 Zhong Zhu Medicine & Life Science Excellent Teacher Award (Research Award-Special Class) 2017
2014 Science and Technology Award of Higher Education of China (First Class), Ministry of Education, China 2014
Title: Studies on the network-based modulatory mechanism of the holistic therapy of traditional Chinese medicine
2014 Macau Science and Technology Award (Natural Science Second Prize 2014)
Title: Innovative Research Methodologies and Novel Theoretical Basis of the “3-M” Feature of Chinese Herbal Medicine
2013 Macau Bank of China Research Award (2013)
One award every year for good research quality in Chinese Medicine in Macau
Professional Activities
Memberships

  • The Specialty Committee on Immunology of Traditional Chinese Medicine of the World Federation of Chinese Medicine Societies (Executive Council)
  • BPMNI Consortium (Executive Council)
  • Macau Life Science Institute（Honorary Advisor）
  • Macau Society of Clinical Oncology (MSCO) (Executive Council)
  • Macau Society of Pharmacology (Executive Council)
  • The Specialty Committee of the World Federation of Chinese Medicine Societies (Member)
  • American Association for Cancer Research (Active Member)
  • The Consortium for Globalization of Chinese Medicine (Active Member)
  • The Association for Promotion of Science and Technology of Macau (Active member)

Active reviewers and editorial board

  • NSFC Grant review committee member
  • Deputy Editor in Chief of Pharmacological Research (IF 10.334)
  • Editorial Board member of Engineering (IF 12.834), representing journal for Chinese Academic of Engineering.
  • Editorial Board member of Antioxidants and Redox Signaling (IF 7.468)
  • Section Editor of Stem Cell Reviews and Reports “Immune system, cell therapy and tissue regeneration” (IF 6.692)
  • Lead guest editor of special issue “The Application of Computational Biology in Cancer Research” in BioMed Research International (IF 3.246)
  • Lead guest editor of special issue “The Advanced Pharmacological Research of Chinese Herbal Medicines in Cancer and Inflammation” in Pharmacological Research (IF 10.334)

Social Service

  • Judge of the Hong Kong Student Science Project Competition 2012-present

License Hold

  • Hong Kong Registered Medical Laboratory Technologist Part I